Effect of Ezetimibe on Insulin Sensitivity and Lipid Profile in Obese and Dyslipidaemic Patients

[1] Boden G.(2001)Obesity, free fatty acids, and insulin resistance Curr Opin Endocrinol Diabetes 8 235-239

[2] Kelley DE(2001)Goodpaster BH. Skeletal muscle triglyceride: an aspect of regional adiposity and insulin resistance Diabetes Care 24 933-941

[3] Kim JK(2005)Adipocyte-specific overexpression of FOXC2 prevents diet-induced increases in intramuscular fatty acyl CoA and insulin resistance Diabetes 54 1657-1663

[4] Kim HJ(2004)Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes J Clin Endocrinol Metab 89 4649-4955

[5] Park SY(2005)Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions Clin Pharmacokinet 44 467-494

[6] Bajaj M(2002)for the Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia Am J Cardiol 90 1092-1097

[7] Suraamomkul S(2003)Ezetimibe for management of hypercholesterolemia Ann Pharmacother 37 839-848

[8] Kashyap S(2001)Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2486-2497

[9] Cusi K(1979)Glucose clamp technique: a method for quantifying insulin secretion and resistance Am J Physiol 237 E214-E223

[10] Mandarino L(1989)Methods of determining samples sizes in clinical trials Indian Pediatr 26 115-121

[1] Boden G.(2001)Obesity, free fatty acids, and insulin resistance Curr Opin Endocrinol Diabetes 8 235-239

[2] Kelley DE(2001)Goodpaster BH. Skeletal muscle triglyceride: an aspect of regional adiposity and insulin resistance Diabetes Care 24 933-941

[3] Kim JK(2005)Adipocyte-specific overexpression of FOXC2 prevents diet-induced increases in intramuscular fatty acyl CoA and insulin resistance Diabetes 54 1657-1663

[4] Kim HJ(2004)Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes J Clin Endocrinol Metab 89 4649-4955

[5] Park SY(2005)Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions Clin Pharmacokinet 44 467-494

[6] Bajaj M(2002)for the Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia Am J Cardiol 90 1092-1097

[7] Suraamomkul S(2003)Ezetimibe for management of hypercholesterolemia Ann Pharmacother 37 839-848

[8] Kashyap S(2001)Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA 285 2486-2497

[9] Cusi K(1979)Glucose clamp technique: a method for quantifying insulin secretion and resistance Am J Physiol 237 E214-E223

[10] Mandarino L(1989)Methods of determining samples sizes in clinical trials Indian Pediatr 26 115-121